Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01331603|
Recruitment Status : Unknown
Verified March 2011 by Wolfson Medical Center.
Recruitment status was: Not yet recruiting
First Posted : April 8, 2011
Last Update Posted : April 8, 2011
Recently, it has been demonstrated that iron overload is associated with the appearance of labile plasma iron (LPI).
LPI is redox active and is rapidly taken up by cells, leading to a rise in the labile iron pool (LIP) and catalyzing generation of reactive oxygen species (ROS), which can lead to cellular damage.
The LPI data are mostly derived from thalassemia iron overload research , however, there are a few data describing LPI and its correlations with the classical iron overload parameters (ferritin, TSAT) in acute anemias such as MDS Therefore we are going to assess LPI in iron overloaded myelodysplastic syndromes (MDS) (low and high risk) and primary myelofibrosis, in order to assess whether it can be used as alternative to the routinely used parameters; TSAT and ferritin levels.
|Condition or disease|
|Myelodysplastic Syndrome Primary Myelofibrosis|
Approximately 60-80% of patients with myelodysplastic syndromes (MDS) present with symptomatic anemia and 80-90%, of these, will require red blood cell (RBC) transfusions. Excess transfusional iron causes iron overload (IO) which is characterized by elevated serum ferritin (> 1000ng/ml) and transferrin saturation (TSAT > 50%) levels.
Assessment of IO using serum ferritin and TSAT levels is not accurate enough and this is due to changes in serum ferritin and TSAT during any inflammatory condition.
Since serum ferritin is considered as a positive acute phase reactant and therefore inflammatory state can lead to an increase in serum ferritin levels and so does not reflect the exact amount of iron overload.
In contrast TSAT can decrease during inflammation and in addition it follows diurnal variations.The aim of our present study is to asses the levels of LPI in patients with in iron overloaded MDS patients (low and high risk), and also patients with primary myelofibrosis, in order to find out any laboratory correlations between LPI, TSAT and srum ferritin levels.
The study will contain 50 patients low+high risk MDS patients and patients with primary myelofibrosis with iron overloaded. The risk stratification of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring System)
After ICF (Informed Consent Form) has been signed by the patients the following laboratory tests will be taken once during the study:
- Ferritin (local laboratory)
- Transferrin Saturation (local laboratory)
- CRP (local laboratory)
- LPI (feROS™ eLPI from Aferrix Ltd., Tel- Aviv, Israel)
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters.|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||January 2013|
MDS and primary myelofibrosis patients
patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
- The value of Ferritin,Transferrin Saturation,CRP and LPI at the blood samples [ Time Frame: 1 year ]
The blood samples should be taken at least one week apart from last blood transfusion.
In case of infection or acute inflammation , blood samples should be taken only one week after resolution of these conditions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01331603
|Contact: Ghoti Hussam, MD||: email@example.com|
|Wolfson Medical Center||Not yet recruiting|
|Contact: Ghoti Hussam, MD 970-35028110 firstname.lastname@example.org|
|Principal Investigator:||Ghoti Hussam, MD||Hematolgy Department of Wolfson Medical Center|